The latest biotech news

News and Trends 12 Sep 2016

CRISPR Therapeutics applies to go Public in another Massive IPO

The wait is over: CRISPR Therapeutics has turned up the heat on its rivals with an IPO filing of €80M, but this figure could be a lowball. Everyone saw it coming – the only question was, when would CRISPR Therapeutics file for an IPO? News arrived today that the company had finally applied to the US […]

September 12, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 12 Sep 2016

Sanofi & Google Joint Venture could Revolutionize Diabetes

Sanofi and Verily, formerly Google Life Sciences, have signed a deal to form a €444M joint venture, Onduo. Its aim is to integrate medicine and microelectronics to tackle diabetes. Steve Jobs prophesied that “the biggest innovations of the twenty-first century will be the intersection of biology and technology,” and it appears that Verily, a division of […]

September 12, 2016 - 3 minutesmins - By Evelyn Warner

vienna biotech valneva sanochemia aop pharma

News and Trends 12 Sep 2016

Grüßgott, get to Meet 9 exciting Biotechs from Vienna

Classical music, the Danube, Schnitzel, and apple strüdel – a typical combination of Vienna. The city has also been at the top of rankings for quality of life, innovation, and popular host for conferences. But what about Biotech? Once one of the most influential cities in Europe, Vienna might now be somewhat under the radar […]

September 12, 2016 - 6 minutesmins - By Denise Neves Gameiro

News and Trends 10 Sep 2016

This Dutch BioArtist could be the Mistress of Natural Forces

Roos Meerman is a force to be reckoned with in the BioArt world – she has been racking up awards and just took home the 2016 BioArt & Design Award. Her work focuses on the manipulation of materials with natural forces like sound and temperature. Roos Meerman is a Dutch bioartist whose work on natural […]

September 10, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 9 Sep 2016

How to get Antibiotic free Bioproduction in Biotech with Delphi Genetics

After Vienna, it’s time to jump in the middle of the Paris-Amsterdam-Frankfurt triangle in the BioPark of Brussels South in Belgium. We will meet a company who can answer the problem of antibiotic use in the bacterial strains selection whilst, at the same time, increasing bioproduction yield. Our Biotech of the week, Delphi Genetics. City: Gosselies […]

September 9, 2016 - 4 minutesmins - By Jerome Topsent

News and Trends 9 Sep 2016

Novel biopharma’s therapy for Traumatic Brain Injury heads to Phase III

A German biotech has surfaced with a promising new drug for traumatic brain injury: vasopharm’s Nitrous Oxide Synthase inhibitor is starting Phase III. In news from the novel and obscure, someone has taken an interest in Nitrous Oxide Synthase (NOS). That someone is vasopharm GmbH, a small German biopharmaceutical company interested in cerebrovascular diseases. The company has […]

September 9, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 8 Sep 2016

Allergan seizes visionary Optogenetic Therapy from US Startup

Allergan is diving into gene therapy with the acquisition of RetroSense Therapeutic’s new early clinical candidate, RST-001. The drug aims to remedy Retinitis Pigmentosa, which affects between 13 and 44 in 100k people worldwide. Allergan has just acquired RetroSense Therapeutics as part of their ongoing effort in eye care. The core of the deal was […]

September 8, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 7 Sep 2016

Building Life from DNA Legos, a Review of Synthetic Biology

It sounds like a lot of fun, but DNA legos are serious: they represent the core concept of synthetic biology, a field with the potential to solve major issues in public health, society and the environment. Here’s a survey of this exciting new area of development. Major thanks to Eshna Gogia at Helixworks for letting us use her article as a source! […]

September 7, 2016 - 7 minutesmins - By Evelyn Warner

News and Trends 7 Sep 2016

Promising Boston-based CRISPR Startup hits up Horizon to fix Gene Misregulation

An American outfit from Third Rock Ventures, Fulcrum Therapeutics, has made a deal with Horizon to access its catalogue of genetic anomalies. The collaboration will target diseases arising from gene misregulation. Horizon Discovery has announced a collaboration with Fulcrum Therapeutics, launched earlier this year by Third Rock Ventures, to target diseases caused by gene regulation malfunction. Fulcrum […]

September 7, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 6 Sep 2016

Denmark: The ‘Best CEO of the World’ to retire at Year’s End

The CEO of Novo Nordisk, who was named ‘Best CEO in the World’ by the Harvard Business Review in October 2015, will not have a chance to dominate the ranking again next year. He will retire by the end of the year (and have some well-deserved holidays). Lars Sorensen, or rather, Sørensen, joined the world-leading producer […]

September 6, 2016 - 2 minutesmins - By Philip Hemme

News and Trends 6 Sep 2016

“This Phase I could Pioneer Needle-free Vaccines”, DBV’s CEO

How annoying are needle vaccinations? Very … But the French billion-euro Biotech DBV Technologies wants to bring a paradigm shift via its Anti-allergy Patch platform! I got to chat with the founder & CEO, Pierre-Henri Benhamou, for more insights. DBV’s success continues to amaze me. It’s not only close to solving the global peanut and […]

September 6, 2016 - 3 minutesmins - By Philip Hemme

News and Trends 6 Sep 2016

“This 30M Series A will help us bring RNA Therapeutics to Immuno-Oncology”

Rigontec is taking a totally new RNA-based approach to immuno-oncology via the RIG-I receptors. The company extended its Series A fundraising to a third round, and some of the top European VC’s doubled its cash pile to almost €30M. Since launching in early 2014, Munich-based Rigontec has broken with traditional immuno-oncology and pioneered a new RNA avenue […]

September 6, 2016 - 4 minutesmins - By Evelyn Warner

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

CRISPR Therapeutics applies to go Public in another Massive IPO

Sanofi & Google Joint Venture could Revolutionize Diabetes

Grüßgott, get to Meet 9 exciting Biotechs from Vienna

This Dutch BioArtist could be the Mistress of Natural Forces

How to get Antibiotic free Bioproduction in Biotech with Delphi Genetics

Novel biopharma’s therapy for Traumatic Brain Injury heads to Phase III

Allergan seizes visionary Optogenetic Therapy from US Startup

Building Life from DNA Legos, a Review of Synthetic Biology

Promising Boston-based CRISPR Startup hits up Horizon to fix Gene Misregulation

Denmark: The ‘Best CEO of the World’ to retire at Year’s End

“This Phase I could Pioneer Needle-free Vaccines”, DBV’s CEO

“This 30M Series A will help us bring RNA Therapeutics to Immuno-Oncology”

Subscribe to our newsletter to get the latest biotech news!